CO2023016940A2 - Terapia de células t con receptor de antígeno quimérico específico de cd19 - Google Patents

Terapia de células t con receptor de antígeno quimérico específico de cd19

Info

Publication number
CO2023016940A2
CO2023016940A2 CONC2023/0016940A CO2023016940A CO2023016940A2 CO 2023016940 A2 CO2023016940 A2 CO 2023016940A2 CO 2023016940 A CO2023016940 A CO 2023016940A CO 2023016940 A2 CO2023016940 A2 CO 2023016940A2
Authority
CO
Colombia
Prior art keywords
antigen receptor
chimeric antigen
cell therapy
specific chimeric
car
Prior art date
Application number
CONC2023/0016940A
Other languages
English (en)
Spanish (es)
Inventor
Otero Manel Juan
Ispizua Álvaro Urbano
Capdevila Mariona Pascal
Ribes Jordi Yagüe
González Julio Delgado
Reyner Jordi Esteve
Castellà María Castellà
Barado Ana Boronat
Original Assignee
Fundacio De Recerca Clinic Barcelona Inst Dinvestigacions Biomediques August Pi I Sunyer
Hospital Clinic Barcelona
Univ Barcelona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio De Recerca Clinic Barcelona Inst Dinvestigacions Biomediques August Pi I Sunyer, Hospital Clinic Barcelona, Univ Barcelona filed Critical Fundacio De Recerca Clinic Barcelona Inst Dinvestigacions Biomediques August Pi I Sunyer
Publication of CO2023016940A2 publication Critical patent/CO2023016940A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CONC2023/0016940A 2021-05-06 2023-12-05 Terapia de células t con receptor de antígeno quimérico específico de cd19 CO2023016940A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/ES2021/070316 WO2022234158A1 (es) 2021-05-06 2021-05-06 Terapia de células t con receptor de antígeno quimérico específico de cd19
PCT/EP2022/062374 WO2022234134A1 (en) 2021-05-06 2022-05-06 Cd19-specific chimeric antigen receptor t-cell therapy

Publications (1)

Publication Number Publication Date
CO2023016940A2 true CO2023016940A2 (es) 2024-02-05

Family

ID=76355528

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0016940A CO2023016940A2 (es) 2021-05-06 2023-12-05 Terapia de células t con receptor de antígeno quimérico específico de cd19

Country Status (11)

Country Link
US (1) US20240398945A1 (cg-RX-API-DMAC10.html)
EP (1) EP4334357A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024519529A (cg-RX-API-DMAC10.html)
AU (1) AU2022270952A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023023061A2 (cg-RX-API-DMAC10.html)
CA (1) CA3219214A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023003299A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023016940A2 (cg-RX-API-DMAC10.html)
JO (1) JOP20230269A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023013088A (cg-RX-API-DMAC10.html)
WO (2) WO2022234158A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025040765A (ja) * 2023-09-12 2025-03-25 国立大学法人三重大学 Ｃａｒをコードする核酸分子とそれを含むベクター、ｃａｒ、ｃａｒを含む免疫細胞とその細胞を含む医薬組成物、細胞傷害活性を向上させる方法、並びにｃａｒを含む免疫細胞の製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
SI2997141T1 (sl) * 2013-05-13 2023-04-28 Cellectis CD19 specifični himerni antigenski receptor in njegova uporaba
JP7089806B2 (ja) * 2017-12-06 2022-06-23 アブクロン・インコーポレイテッド 悪性ｂ細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途
WO2019119822A1 (en) * 2017-12-23 2019-06-27 Uwell Biopharma Inc. Pharmaceutical chimeric receptor composition and method thereof
CN108047332B (zh) * 2018-01-15 2021-08-24 阿思科力(苏州)生物科技有限公司 以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用
US12331114B2 (en) * 2018-02-13 2025-06-17 Indian Institute Of Technology Bombay Humanized anti-CD19 chimeric antigen receptor, its nucleic acid sequence and its preparation
WO2020180551A1 (en) * 2019-03-05 2020-09-10 Promab Biotechnologies, Inc. Car-t cells with humanized cd19 scfv
KR20210137085A (ko) * 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도

Also Published As

Publication number Publication date
CA3219214A1 (en) 2022-11-10
MX2023013088A (es) 2024-01-24
CL2023003299A1 (es) 2024-07-05
BR112023023061A2 (pt) 2024-01-30
EP4334357A1 (en) 2024-03-13
JOP20230269A1 (ar) 2023-10-26
US20240398945A1 (en) 2024-12-05
WO2022234134A1 (en) 2022-11-10
AU2022270952A1 (en) 2023-11-16
JP2024519529A (ja) 2024-05-15
WO2022234158A1 (es) 2022-11-10

Similar Documents

Publication Publication Date Title
CO2022000281A2 (es) Receptores de linfocitos t de mage-a4 y métodos de uso de estos
AR117685A1 (es) Antígeno quimérico y receptores de células t y métodos de uso
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
CO2019011155A2 (es) Anticuerpos anti-ilt4 y fragmentos de unión a antígeno
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
MX2020008184A (es) Receptores de antigeno quimericos dirigidos a cd70.
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
CO2019013654A2 (es) Receptores de antígenos quiméricos que se dirigen a flt3
BR112022008522A2 (pt) Usos de receptores de antígeno quimérico anti-bcma
MX2019008503A (es) Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos.
CO2019003809A2 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso
CL2017000250A1 (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso
EA202190243A1 (ru) Применение химерных антигенных рецепторов к bcma
CL2019002314A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
CL2021001260A1 (es) Anticuerpos anti-sirpa humanizados
UY37589A (es) COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR)
PE20210488A1 (es) Anticuerpos especificos para gucy2c y sus usos
UY37590A (es) COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR)
HN2012000708A (es) Anticuerpos monoclonales frente a progastrina y sus uso
CL2018001334A1 (es) Anticuerpos y conjugados anticuerpo-fármaco anti-5t4.
CL2009000567A1 (es) Anticuerpo monoclonal que enlaza especificamente tyrp1 humano; fragmento de cualquiera de los anticuerpos antes indicado; acido nucleico que codifica en anticuerpo o fragmento; vector de expresion; celula recombinante; uso del anticuerpo o fragmento para tratar cancer.
MX360984B (es) Anticuerpos monoclonales para el uso en la diagnosis y la terapia de cánceres y de enfermedades autoinmunes.
MX2021015545A (es) Moduladores de cot y metodos de uso de estos.
CO2022011869A2 (es) Antígeno expresado preferentemente en receptores de linfocitos t de melanoma (prame) y sus métodos de uso
WO2018118494A3 (en) Use of car-modified human natural killer cells to treat cancer